top of page
Drug Development Pipeline
Advancing precision-engineered T cell engager therapies across autoimmunity and oncology, with a focus on rapid clinical proof-of-concept and scalable development
Programs
Lead program in autoimmunity, with expanding pipeline in oncology
ATX-101
Designed to enable durable immune reset through targeted elimination of disease-driving cells
ATX-201
Designed to mitigate antigen escape and improve durability of response in oncology
Preclinical
Preclinical
bottom of page